Zynerba Pharmaceuticals (ZYNE) PT Lowered to $8.50 at Roth Capital, After Study Misses Endpoints
Tweet Send to a Friend
Roth Capital analyst Scott R. Henry lowered the price target on Zynerba Pharmaceuticals (NASDAQ: ZYNE) to $8.50 (from $11.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
